Skip to main content

A blood-based biomarker panel to risk-stratify mild traumatic brain injury.

Publication ,  Journal Article
Sharma, R; Rosenberg, A; Bennett, ER; Laskowitz, DT; Acheson, SK
Published in: PLoS One
2017

Mild traumatic brain injury (TBI) accounts for the vast majority of the nearly two million brain injuries suffered in the United States each year. Mild TBI is commonly classified as complicated (radiographic evidence of intracranial injury) or uncomplicated (radiographically negative). Such a distinction is important because it helps to determine the need for further neuroimaging, potential admission, or neurosurgical intervention. Unfortunately, imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI) are costly and not without some risk. The purpose of this study was to screen 87 serum biomarkers to identify a select panel of biomarkers that would predict the presence of intracranial injury as determined by initial brain CT. Serum was collected from 110 patients who sustained a mild TBI within 24 hours of blood draw. Two models were created. In the broad inclusive model, 72kDa type IV collagenase (MMP-2), C-reactive protein (CRP), creatine kinase B type (CKBB), fatty acid binding protein-heart (hFABP), granulocyte-macrophage colony-stimulating factor (GM-CSF) and malondialdehyde modified low density lipoprotein (MDA-LDL) significantly predicted injury visualized on CT, yielding an overall c-statistic of 0.975 and a negative predictive value (NPV) of 98.6. In the parsimonious model, MMP-2, CRP, and CKBB type significantly predicted injury visualized on CT, yielding an overall c-statistic of 0.964 and a negative predictive value (NPV) of 97.2. These results suggest that a serum based biomarker panel can accurately differentiate patients with complicated mild TBI from those with uncomplicated mild TBI. Such a panel could be useful to guide early triage decisions, including the need for further evaluation or admission, especially in those environments in which resources are limited.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

PLoS One

DOI

EISSN

1932-6203

Publication Date

2017

Volume

12

Issue

3

Start / End Page

e0173798

Location

United States

Related Subject Headings

  • Tomography, X-Ray Computed
  • Prospective Studies
  • Predictive Value of Tests
  • Neuroimaging
  • Middle Aged
  • Matrix Metalloproteinase 2
  • Malondialdehyde
  • Male
  • Lipoproteins, LDL
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sharma, R., Rosenberg, A., Bennett, E. R., Laskowitz, D. T., & Acheson, S. K. (2017). A blood-based biomarker panel to risk-stratify mild traumatic brain injury. PLoS One, 12(3), e0173798. https://doi.org/10.1371/journal.pone.0173798
Sharma, Richa, Alexandra Rosenberg, Ellen R. Bennett, Daniel T. Laskowitz, and Shawn K. Acheson. “A blood-based biomarker panel to risk-stratify mild traumatic brain injury.PLoS One 12, no. 3 (2017): e0173798. https://doi.org/10.1371/journal.pone.0173798.
Sharma R, Rosenberg A, Bennett ER, Laskowitz DT, Acheson SK. A blood-based biomarker panel to risk-stratify mild traumatic brain injury. PLoS One. 2017;12(3):e0173798.
Sharma, Richa, et al. “A blood-based biomarker panel to risk-stratify mild traumatic brain injury.PLoS One, vol. 12, no. 3, 2017, p. e0173798. Pubmed, doi:10.1371/journal.pone.0173798.
Sharma R, Rosenberg A, Bennett ER, Laskowitz DT, Acheson SK. A blood-based biomarker panel to risk-stratify mild traumatic brain injury. PLoS One. 2017;12(3):e0173798.

Published In

PLoS One

DOI

EISSN

1932-6203

Publication Date

2017

Volume

12

Issue

3

Start / End Page

e0173798

Location

United States

Related Subject Headings

  • Tomography, X-Ray Computed
  • Prospective Studies
  • Predictive Value of Tests
  • Neuroimaging
  • Middle Aged
  • Matrix Metalloproteinase 2
  • Malondialdehyde
  • Male
  • Lipoproteins, LDL
  • Humans